{"gene":"STAT5A","run_date":"2026-06-10T07:46:42","timeline":{"discoveries":[{"year":1997,"finding":"Stat5a is the principal and obligate mediator of prolactin-induced mammary lobuloalveolar development and lactogenesis; targeted deletion of Stat5a in mice abolishes terminal differentiation of mammary epithelium and lactation, despite Stat5b having 96% similarity and a superimposable expression pattern.","method":"Gene targeting (knockout mice), mammary gland histology, lactation phenotyping","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic KO with defined cellular phenotype, replicated across multiple subsequent studies, clear non-redundancy with Stat5b established by direct comparison","pmids":["9009201"],"is_preprint":false},{"year":1998,"finding":"Stat5a and Stat5b have essential but often redundant roles in cytokine responses mediated by growth hormone and prolactin; individual and double-knockout mice show that Stat5a is specifically required for prolactin-driven mammary responses while erythropoietin responses are largely unaffected.","method":"Individual and combined gene targeting (knockout mice), cytokine response phenotyping","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with defined phenotypic readouts, broadly replicated, multi-cytokine epistasis established","pmids":["9630227"],"is_preprint":false},{"year":1996,"finding":"STAT5 forms a physical complex with the glucocorticoid receptor (GR); this complex binds DNA independently of classical GRE sequences and enables GR to act as a transcriptional co-activator enhancing STAT5-dependent transcription, while simultaneously diminishing GRE-driven glucocorticoid responses.","method":"Co-immunoprecipitation, DNA-binding assays, transcriptional reporter assays, transfection in mammalian cells","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP plus functional reporter assays, replicated by independent lab (Lechner 1997)","pmids":["8878484"],"is_preprint":false},{"year":1997,"finding":"Stat5a is activated by IL-2 and is specifically required for IL-2-induced upregulation of the IL-2 receptor alpha chain (IL-2Rα/CD25); defective IL-2Rα expression in Stat5a-/- splenocytes leads to markedly decreased proliferative responses to low-affinity IL-2 concentrations.","method":"Stat5a knockout mice, splenocyte proliferation assays, IL-2Rα expression analysis, IL-2 dose-response","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic KO with specific mechanistic readout (receptor expression) and dose-response validation","pmids":["9390692"],"is_preprint":false},{"year":1995,"finding":"IL-2 and IL-15 rapidly induce tyrosine phosphorylation of STAT5 (and STAT3) and activate STAT5-containing DNA-binding complexes in human T cells; JAK1 and JAK3 are co-phosphorylated, establishing STAT5 as downstream of the JAK1/JAK3 axis for IL-2 family cytokines.","method":"Tyrosine phosphorylation assays, electrophoretic mobility shift assay (EMSA), immunoprecipitation of JAKs in human T cells","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (phosphorylation + DNA binding + kinase IP), single lab","pmids":["7568001"],"is_preprint":false},{"year":2000,"finding":"PTP1B specifically dephosphorylates and inactivates prolactin-activated STAT5a and STAT5b; overexpression of PTP1B inhibits nuclear translocation of STAT5 and suppresses PRL-dependent beta-casein gene transcription; substrate-trapping PTP1B mutants co-precipitate endogenous tyrosine-phosphorylated STAT5.","method":"In vitro phosphatase assay, overexpression in COS7 and COMMA-1D mammary cells, retrovirus-mediated overexpression, substrate-trapping co-precipitation, reporter gene assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro enzymatic assay plus substrate-trapping co-precipitation plus functional transcriptional readout, single lab but multiple orthogonal methods","pmids":["10993888"],"is_preprint":false},{"year":2003,"finding":"Shp-2 (but not Shp-1) specifically interacts with tyrosine-phosphorylated STAT5A in vivo, accelerates its dephosphorylation, and dephosphorylation of STAT5A is dramatically delayed in Shp-2-deficient cells; interaction is phospho-tyrosine-dependent.","method":"Phosphopeptide affinity purification, co-immunoprecipitation, Shp-2-deficient cells, phosphatase assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — biochemical purification plus co-IP plus genetic null cells, single lab with multiple orthogonal approaches","pmids":["12615921"],"is_preprint":false},{"year":1997,"finding":"The insulin receptor (IR) directly phosphorylates STAT5 in vitro; insulin stimulates tyrosine phosphorylation and DNA-binding activity of STAT5 in liver, skeletal muscle, and adipose tissue; STAT5b C-terminal domain interacts with the IR cytoplasmic domain identified by yeast two-hybrid.","method":"Yeast two-hybrid, in vitro kinase assay with purified IR kinase domain, in vivo tyrosine phosphorylation, EMSA on tissue extracts","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution kinase assay plus yeast two-hybrid plus in vivo tissue validation, single lab but multiple orthogonal methods","pmids":["9122188"],"is_preprint":false},{"year":2007,"finding":"Oncogenic Flt3-ITD directly phosphorylates and activates STAT5 independently of Src family kinases and JAK kinases; demonstrated by in vitro kinase assay showing STAT5 as direct Flt3 substrate, and by SOCS1 overexpression (which inhibits IL-3- but not Flt3-ITD-mediated STAT5 activation).","method":"In vitro kinase assay, small-molecule kinase inhibitors, Src-deficient cell lines, JAK2/Tyk2-deficient cells, SOCS1 overexpression","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — in vitro kinase reconstitution plus multiple genetic/pharmacologic epistasis approaches, single lab","pmids":["17356133"],"is_preprint":false},{"year":2003,"finding":"JAK2 and STAT5a are essential for prolactin-induced RANKL expression in mammary epithelial cells; identified a GAS element in the RANKL promoter conferring PRL responsiveness, demonstrated by dominant-negative mutants of JAK2 and STAT5, and reconstitution of the JAK2/STAT5 pathway in COS7 cells.","method":"Dominant-negative mutants, luciferase reporter assay, pathway reconstitution in COS7 cells, promoter deletion analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — dominant-negative epistasis plus reconstitution plus promoter mapping, single lab","pmids":["12952963"],"is_preprint":false},{"year":1998,"finding":"JAK2 kinase domain is sufficient for interaction with and phosphorylation of STAT5; the STAT5 SH2 domain R618K mutation abolishes JAK2-mediated phosphorylation; a single phosphotyrosine-SH2 interaction is sufficient for STAT5 dimerization but produces dimers that bind DNA very inefficiently; C-terminal deletion causes STAT5 hyperphosphorylation.","method":"Yeast-based expression system with integrated reporter, site-directed mutagenesis, co-immunoprecipitation under stringent conditions, deletion mutant analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — mutagenesis plus yeast reconstitution system with rigorous controls, single lab","pmids":["9575217"],"is_preprint":false},{"year":1998,"finding":"Prolactin receptor (PRLR) regulates STAT5 tyrosine phosphorylation and nuclear translocation by two separate mechanisms: phosphorylation is independent of PRLR phosphotyrosines, whereas nuclear translocation specifically requires the C-terminal tyrosine of the PRLR Nb2 form (Tyr382).","method":"PRLR phosphotyrosine mutant analysis, overexpression of natural and mutant PRLR forms in HC11 and 293-LA cells, subcellular fractionation, DNA-binding assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — site-directed mutagenesis of receptor plus nuclear translocation readout, single lab with two cell systems","pmids":["9516478"],"is_preprint":false},{"year":2003,"finding":"STAT5A, but not STAT5B alone, is sufficient to promote adipogenesis in non-precursor fibroblast cell lines and induces expression of early and late adipogenic markers; STAT5A physically associates with the glucocorticoid receptor during adipogenesis in a regulated manner.","method":"Ectopic expression in BALB/c and NIH-3T3 cells, morphological and biochemical adipogenesis markers, co-immunoprecipitation during differentiation","journal":"Diabetes","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — ectopic expression with multiple readouts plus co-IP, single lab","pmids":["12540601"],"is_preprint":false},{"year":2004,"finding":"Physical interaction between STAP-2/BKS and STAT5 occurs via the PH- and SH2-like domains of STAP-2/BKS binding the C-terminal region of STAT5; STAP-2/BKS co-localizes with STAT5 in the cytoplasm of resting cells and dissociates upon STAT5 phosphorylation; overexpression of STAP-2/BKS diminishes cytokine-induced STAT5 tyrosine phosphorylation and transcriptional activation.","method":"Co-immunoprecipitation, intracellular staining, mutational analysis, STAP-2/BKS-deficient mice thymocytes, overexpression assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — co-IP plus mutational domain mapping plus functional readout plus KO mice, single lab","pmids":["15611091"],"is_preprint":false},{"year":2013,"finding":"Unphosphorylated STAT5A binds to heterochromatin protein 1α (HP1α) and stabilizes heterochromatin; expression of unphosphorylatable STAT5A produces similar global gene repression as HP1α overexpression, with most co-repressed genes implicated in cancer development; expressing unphosphorylated STAT5A or HP1α inhibits colon cancer xenograft growth.","method":"Co-immunoprecipitation, transcriptome profiling, mouse xenograft models, unphosphorylatable STAT5A mutant expression","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus transcriptome plus in vivo xenograft, single lab with multiple orthogonal methods","pmids":["23733954"],"is_preprint":false},{"year":2010,"finding":"Serine phosphorylation of Stat5a at residues 725 and 779 is a prerequisite for oncogenic/leukemogenic transformation; mutating these serines abolishes the leukemogenic potential of constitutively active Stat5a in bone marrow transplants, while normal hematopoietic reconstitution functions are preserved.","method":"Site-directed mutagenesis of Stat5a serine residues, genetic complementation in Stat5-null cells, in vivo bone marrow transplantation leukemia model","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — mutagenesis plus in vivo reconstitution in primary null cells plus transplantation model, single lab but multiple orthogonal approaches","pmids":["20508164"],"is_preprint":false},{"year":1997,"finding":"STAT5 activation correlates with and is required for erythropoietin receptor (EpoR)-mediated erythroid differentiation; EpoR Tyr343 or Tyr401 independently activates STAT5 and induces erythroid differentiation; dominant-negative STAT5 suppresses EPO-dependent erythroid differentiation.","method":"Chimeric EpoR mutants with Y→F substitutions, dominant-negative STAT5 overexpression, globin expression assay in erythroleukemia ELM-I-1 cells","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — receptor mutagenesis plus dominant-negative epistasis plus functional differentiation readout, single lab","pmids":["9079629"],"is_preprint":false},{"year":2003,"finding":"LMW-PTP associates with and dephosphorylates STAT5 in megakaryocytic cells; interaction involves the C-terminal domain of STAT5 (not exclusively the phosphotyrosine-active site interaction), identifying LMW-PTP as a STAT5 phosphatase.","method":"Co-immunoprecipitation in DAMI megakaryocytic cells, phosphatase assay, domain mapping","journal":"Biochemical and biophysical research communications","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single co-IP/phosphatase assay, single lab, single method set","pmids":["14637146"],"is_preprint":false},{"year":2008,"finding":"STAT5 physically interacts with Runx1, Runx2, and Runx3 via its DNA-binding domain and α-helix loop; STAT5 retains Runx proteins in the cytoplasm; STAT5-Runx interaction mutually inhibits transcriptional activity of both, and Runx proteins inhibit STAT5 DNA-binding activity.","method":"Co-immunoprecipitation, reporter assay, subcellular localization (nuclear/cytoplasmic fractionation), DNA-binding assay, endogenous target gene (CIS) expression in Ba/F3 cells","journal":"Journal of biochemistry","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — co-IP plus functional reporter plus localization plus endogenous target gene, single lab with multiple methods","pmids":["18296717"],"is_preprint":false},{"year":2017,"finding":"O-GlcNAcylation of STAT5 promotes its tyrosine phosphorylation, oligomerization, and oncogenic transactivation; a hyperactive STAT5 mutant lacking O-GlcNAcylation shows decreased tyrosine phosphorylation, oligomerization, transactivation potential, and complete loss of oncogenic transformation capacity.","method":"O-GlcNAcylation site mutagenesis, tyrosine phosphorylation assays, oligomerization assays, oncogenic transformation assays in hematopoietic cells","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — mutagenesis plus multiple biochemical readouts plus functional transformation assay, single lab","pmids":["28074064"],"is_preprint":false},{"year":2014,"finding":"In oncogenic FLT3/KIT-driven leukemic cells, FAK activates Rac1 via RacGEF Tiam1, which activates PAK1; PAK1 promotes nuclear translocation of Stat5; pharmacologic inhibition of PAK1 inhibits Stat5 nuclear translocation and prolongs survival of leukemic mice.","method":"FAK/PAK1 pharmacologic inhibitors, in vivo leukemia mouse models, subcellular fractionation, survival analysis of leukemic mice","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo epistasis with inhibitors plus nuclear translocation readout, single lab","pmids":["25456130"],"is_preprint":false},{"year":2016,"finding":"HDAC6 deacetylates the STAT5a coactivator HMGN2 at lysine K2; deacetylated HMGN2 promotes STAT5a-mediated transcription and breast cancer growth; HDAC6 inhibition enhances HMGN2 acetylation with concomitant reduction in STAT5a-mediated signaling.","method":"HDAC6 inhibition in vitro and in vivo, acetylation site identification (K2), co-immunoprecipitation, chromatin assays, breast cancer xenograft models","journal":"Molecular cancer research : MCR","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical acetylation site identification plus functional in vitro/in vivo readout, single lab","pmids":["27358110"],"is_preprint":false},{"year":2014,"finding":"Persistent (but not transient) STAT5 activation recruits p53 to chromatin; genome-wide ChIP shows STAT5 and p53 co-localize at 463 proximal promoter positions in transformed hematopoietic cells; chromatin binding of p53 at these sites is dependent on persistent STAT5 activation.","method":"ChIP-seq, ChIP, reporter assay, STAT5 and p53 inhibition, patient MPN platelet gene expression","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq genome-wide plus functional inhibition readout, single lab","pmids":["24681953"],"is_preprint":false},{"year":2016,"finding":"A mammary-specific intergenic enhancer between the Stat5a and Stat5b loci contains STAT5-binding motifs and drives positive autoregulatory feedback; CRISPR/Cas9 deletion of STAT5-binding sites reduces Stat5 levels in mammary epithelium by ~80% and correspondingly reduces STAT5-dependent gene expression.","method":"ChIP-seq, DNaseI hypersensitivity, CRISPR/Cas9 genome editing in mice, transcriptome analysis","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — CRISPR-based in vivo genome editing with defined molecular and transcriptomic phenotype, supported by ChIP-seq","pmids":["26446995"],"is_preprint":false},{"year":2016,"finding":"The mammary Wap super-enhancer contains a functional hierarchy of STAT5A-binding sites; combinatorial CRISPR/Cas9 mutation of all constituent enhancers is required for the full ~1000-fold induction of Wap expression during pregnancy; disabling STAT5, NFIB, and ELF5 binding sites in the proximal enhancer incapacitates the entire super-enhancer.","method":"ChIP-seq (STAT5A, GR, H3K27ac, MED1), CRISPR/Cas9 combinatorial mutagenesis in mice, reporter assays","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — genome-wide ChIP-seq plus combinatorial CRISPR in vivo mutagenesis with specific phenotypic and transcriptional readouts","pmids":["27376239"],"is_preprint":false},{"year":2021,"finding":"A mitochondrial fraction of STAT5A interacts with the pyruvate dehydrogenase complex (PDC), disrupts PDC integrity, inhibits PDC activity, and promotes the Warburg effect; mitochondrial translocation of STAT5A increases under hypoxic conditions and promotes tumor growth in vivo.","method":"Co-immunoprecipitation of STAT5A with PDC subunits, PDC activity assays, glycolysis/OXPHOS metabolic profiling, hypoxia treatment, xenograft tumor models","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus enzymatic activity assay plus metabolic readout plus in vivo, single lab","pmids":["34148062"],"is_preprint":false},{"year":2005,"finding":"STAT5A physically interacts with and is tyrosine-phosphorylated upon activation of the mu-opioid receptor (MOR) via a Src-dependent mechanism; the YXXL motif (aa 336-339) in the MOR C-terminal tail is required for STAT5A binding; Src inhibitor PP1 abolishes opioid-dependent STAT5A phosphorylation.","method":"Co-immunoprecipitation, GST pulldown from rat brain/COS-7 extracts, site-directed mutagenesis of MOR YXXL motif, Src inhibitor PP1, STAT-responsive reporter gene","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — co-IP plus GST pulldown plus mutagenesis plus reporter assay, single lab","pmids":["15857395"],"is_preprint":false},{"year":2018,"finding":"STAT5a/b is required for RAD51 expression and homologous recombination (HR) DNA repair in prostate cancer via JAK2-dependent induction of Rad51 mRNA; genetic knockdown of STAT5a/b suppresses HR but not NHEJ, and pharmacologic STAT5 inhibition sensitizes prostate cancer to radiation.","method":"Comet assay, clonogenic survival assay, HR/NHEJ reporter assays, RAD51 expression analysis, STAT5a/b siRNA knockdown, xenograft in vivo models, patient-derived 3D explant cultures","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal DNA repair assays plus in vivo xenograft, single lab","pmids":["29483142"],"is_preprint":false},{"year":2021,"finding":"STAT5A negatively regulates MAP2K2 transcription by occupying its promoter, thereby decreasing ERK phosphorylation; YTHDF2 m6A reader promotes STAT5A mRNA degradation by binding its m6A modification site, thus relieving STAT5A-mediated suppression of the MAP2K2/ERK pathway in multiple myeloma.","method":"m6A-RIP-seq, RIP-PCR, ChIP-seq, ChIP-qPCR, siRNA knockdown/overexpression, in vitro and in vivo proliferation assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq plus m6A-RIP-seq plus functional readout, single lab","pmids":["35075244"],"is_preprint":false},{"year":2018,"finding":"Cardiomyocyte-specific Stat5 knockout abolishes late remote ischemic preconditioning (RIPC)-induced cardioprotection against myocardial I/R injury; RIPC requires Stat5 to activate anti-apoptotic signaling (Bcl-2, Bcl-xL), suppress cytochrome c/caspase-3, and activate HIF-1α, IL-10, AKT, and PI3K in cardiac tissue.","method":"Cardiomyocyte-specific Stat5 conditional knockout (Stat5fl/fl; Tnnt2Cre), myocardial infarct size measurement, apoptosis assays, Western blot of signaling proteins","journal":"Cardiovascular research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional tissue-specific KO with defined in vivo phenotype and mechanistic readouts, single lab","pmids":["29365089"],"is_preprint":false},{"year":2013,"finding":"TMPRSS6 expression is directly regulated by STAT5, which binds a STAT5 element in the Tmprss6 promoter; inflammation suppresses TMPRSS6 by reducing STAT5 phosphorylation through a Bmp-Smad-independent mechanism, thereby secondarily increasing hepcidin to regulate iron homeostasis.","method":"ChIP (STAT5 binding to Tmprss6 promoter), in vitro IL-6 treatment, in vivo LPS injection in mice, STAT5 phosphorylation assays","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct ChIP on promoter plus in vivo and in vitro functional readout, single lab","pmids":["24376517"],"is_preprint":false},{"year":2016,"finding":"STAT5 binds directly to the Cyp19a1/aromatase promoter in macrophages to suppress its transcription; loss of STAT5 in macrophages leads to enhanced stromal aromatase expression, increased IL-6, delayed ductal elongation, and enhanced ductal branching during mammary gland development.","method":"Myeloid-specific Stat5 conditional knockout mice, ChIP (STAT5 binding to Cyp19a1 promoter), mammary gland whole-mount analysis, quantitative gene expression","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with defined phenotype plus direct ChIP validation of promoter binding, single lab","pmids":["28606561"],"is_preprint":false},{"year":2016,"finding":"STAT5 inhibition suppresses STAT5 activation, dimerization, and nuclear translocation; the SH2 domain inhibitor AC-4-130 directly binds STAT5 and blocks its SH2-mediated dimerization, establishing the SH2 domain as essential for STAT5 activation and nuclear translocation in AML cells.","method":"Direct STAT5 binding assay, STAT5 dimerization assay, nuclear translocation assay, pharmacologic SH2 domain inhibitor, AML cell lines and patient samples in vitro and in vivo","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding plus dimerization/translocation functional assays, single lab","pmids":["29472718"],"is_preprint":false},{"year":2021,"finding":"STAT5 tetramerization (mediated by N-domain interactions) promotes GM-CSF-induced CCL17 production by monocyte-derived cells, which in turn facilitates integrin VLA-4-dependent pathogenic Th17 cell extravasation in experimental autoimmune encephalomyelitis; STAT5 N-domain double knockin (tetramer-deficient) mice have reduced EAE pathogenesis.","method":"STAT5 tetramer-deficient knockin mice (N-domain mutations), EAE model, flow cytometry, cytokine production assays, CCL17 rescue experiments","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic model with defined domain-specific mutation plus in vivo disease model plus mechanistic rescue, single lab","pmids":["34934004"],"is_preprint":false},{"year":2019,"finding":"STAT5A directly regulates FABP5 transcription by binding to the FABP5 promoter, thereby promoting fatty acid metabolic reprogramming and tumorigenesis in gastric cancer cells.","method":"Luciferase reporter assay, ChIP-qPCR, STAT5A knockdown, lipid content measurements, xenograft tumor models","journal":"European review for medical and pharmacological sciences","confidence":"Low","confidence_rationale":"Tier 3 / Weak — ChIP-qPCR plus reporter assay, single lab, limited mechanistic depth","pmids":["31646566"],"is_preprint":false},{"year":2016,"finding":"STAT5A inhibition de-represses DLX5 expression in bone marrow stromal cells, enhancing osteogenesis; STAT5A knockout mice show increased trabecular and cortical bone mass and prevention of age-related bone loss; STAT5A deletion enhances fracture repair in a murine model.","method":"STAT5A siRNA knockdown in hBMSCs, STAT5A conditional knockout mice, micro-CT bone analysis, fracture callus histology","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO plus in vitro knockdown plus multiple skeletal phenotype readouts, single lab","pmids":["30429452"],"is_preprint":false},{"year":2016,"finding":"Phosphorylated STAT5 (pY694) downregulates NPM1 by impairing the BRCA1-BARD1 ubiquitin ligase that controls NPM1 stability; decreased NPM1 levels suppress p53 expression, enhancing cell survival; NPM1 conversely negatively regulates STAT5 phosphorylation and preserves unphosphorylated STAT5.","method":"Co-immunoprecipitation, knockdown/overexpression, ubiquitin ligase activity assays, p53 expression analysis","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — co-IP plus functional protein stability assays plus bidirectional regulatory readout, single lab","pmids":["28005077"],"is_preprint":false},{"year":1997,"finding":"GR and STAT5 interaction requires intact DNA-binding sites for both factors; GR sites used for synergism with STAT5 at the beta-casein gene promoter are non-classical half-palindromic sites that do not function independently, establishing a novel mode of transcriptional cooperation dependent on both activated STAT5 and GR.","method":"Reporter gene assays in HC11 and COS-7 cells, promoter deletion/mutation analysis, gel shift assay","journal":"Immunobiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter mutagenesis plus reporter assay in two cell systems, single lab","pmids":["9442383"],"is_preprint":false},{"year":2025,"finding":"STAT3 restrains the JAK2-STAT5 transcriptional pathway in dendritic cells, thereby suppressing immunogenic DC function; STAT3 degradation by PROTACs reprograms the DC transcriptional network toward STAT5-driven immunogenicity, enhancing T cell priming and anti-tumor immunity.","method":"PROTAC STAT3 degraders, transcriptomic profiling of dendritic cells, T cell priming assays, in vivo tumor models","journal":"Nature","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic/pharmacologic intervention with transcriptomic and in vivo functional readout, single lab","pmids":["40369063"],"is_preprint":false}],"current_model":"STAT5A is a latent cytoplasmic transcription factor that is tyrosine-phosphorylated (primarily at Y694) by receptor-associated JAKs (especially JAK2) or directly by receptor tyrosine kinases (insulin receptor, Flt3-ITD) downstream of a wide range of cytokines and hormones; upon phosphorylation, STAT5A undergoes SH2-domain-mediated dimerization (and tetramerization via N-domain contacts), nuclear translocation facilitated by signaling intermediates such as PAK1, and sequence-specific DNA binding at GAS elements to activate target gene transcription; its activity is negatively regulated by multiple phosphatases (PTP1B, Shp-2, LMW-PTP); additional post-translational modifications including serine phosphorylation at S725/S779 and O-GlcNAcylation enhance its oncogenic/leukemogenic activity; unphosphorylated STAT5A has a distinct function stabilizing heterochromatin via HP1α; a mitochondrial pool of STAT5A disrupts the pyruvate dehydrogenase complex to promote the Warburg effect; and context-specific transcriptional outputs are shaped by physical interactions with co-regulators including the glucocorticoid receptor, Runx transcription factors, HMGN2/HDAC6, NMI, and STAP-2/BKS, as well as by cell-type-specific autoregulatory enhancers that amplify STAT5A expression in mammary epithelium."},"narrative":{"mechanistic_narrative":"STAT5A is a latent cytoplasmic transcription factor that couples cytokine, hormone, and growth-factor receptors to sequence-specific gene activation and serves as the obligate, non-redundant mediator of prolactin-driven mammary lobuloalveolar development and lactogenesis [PMID:9009201, PMID:9630227]. Activation proceeds through tyrosine phosphorylation by receptor-associated JAK kinases—the JAK2 kinase domain alone is sufficient to bind and phosphorylate STAT5, and the SH2-domain residue R618 is required for this event [PMID:9575217]—as well as by JAK1/JAK3 downstream of IL-2/IL-15 [PMID:7568001]; STAT5 is also a direct substrate of the insulin receptor and of oncogenic Flt3-ITD independently of JAK and Src kinases [PMID:9122188, PMID:17356133]. Phosphorylated STAT5 dimerizes through reciprocal phosphotyrosine–SH2 contacts (the pharmacologic SH2 inhibitor AC-4-130 blocks dimerization and nuclear entry) and can further tetramerize via N-domain interactions to drive specific outputs such as GM-CSF-induced CCL17 in autoimmune inflammation [PMID:29472718, PMID:34934004]; nuclear translocation is promoted by a FAK–Rac1–PAK1 axis in leukemic cells [PMID:25456130]. In the nucleus STAT5A binds GAS elements to control target genes including the IL-2 receptor α chain, RANKL, RAD51, and TMPRSS6, and acts through cell-type-specific and autoregulatory mammary enhancers/super-enhancers that amplify Stat5 expression and Wap induction [PMID:9390692, PMID:12952963, PMID:29483142, PMID:24376517, PMID:26446995, PMID:27376239]. Transcriptional output is shaped by physical partners—the glucocorticoid receptor (cooperating at non-classical half-sites), Runx1/2/3, HMGN2/HDAC6, and the negative regulator STAP-2/BKS [PMID:8878484, PMID:9442383, PMID:18296717, PMID:27358110, PMID:15611091]. Signaling is terminated by the phosphatases PTP1B and Shp-2, which bind phospho-STAT5 and accelerate its dephosphorylation [PMID:10993888, PMID:12615921]. Beyond canonical signaling, post-translational modification by serine phosphorylation at S725/S779 and by O-GlcNAcylation is required for its leukemogenic and oncogenic activity [PMID:20508164, PMID:28074064], unphosphorylated STAT5A binds HP1α to stabilize heterochromatin and repress cancer-associated genes [PMID:23733954], and a mitochondrial pool disrupts the pyruvate dehydrogenase complex to promote the Warburg effect [PMID:34148062]. STAT5A also has tissue-specific physiological roles in erythroid and adipocyte differentiation, bone mass control, and cardioprotective ischemic preconditioning [PMID:9079629, PMID:12540601, PMID:30429452, PMID:29365089].","teleology":[{"year":1996,"claim":"Established that STAT5 is not an isolated activator but physically integrates with nuclear hormone receptor signaling, forming a complex with the glucocorticoid receptor that cooperatively shapes transcriptional output.","evidence":"Co-IP, DNA-binding and reporter assays in mammalian cells, with promoter mutagenesis showing dependence on non-classical GR half-sites","pmids":["8878484","9442383"],"confidence":"High","gaps":["Structural basis of the STAT5-GR interaction not resolved","Generality of half-site cooperation beyond the beta-casein promoter not established"]},{"year":1995,"claim":"Placed STAT5 downstream of IL-2-family cytokine receptors via the JAK1/JAK3 axis, linking tyrosine phosphorylation to DNA-binding complex formation.","evidence":"Phosphorylation assays, EMSA, and JAK immunoprecipitation in human T cells","pmids":["7568001"],"confidence":"Medium","gaps":["Did not distinguish STAT5A from STAT5B contributions","Direct kinase-substrate relationship not reconstituted in vitro"]},{"year":1997,"claim":"Genetic knockout defined STAT5A as the principal, non-redundant mediator of prolactin-induced mammary differentiation and lactation, answering whether the near-identical STAT5A/STAT5B paralogs are functionally interchangeable.","evidence":"Stat5a knockout mice, mammary histology, and lactation phenotyping; extended by individual and combined Stat5a/Stat5b knockouts","pmids":["9009201","9630227"],"confidence":"High","gaps":["Molecular basis for STAT5A vs STAT5B specificity at shared target genes not defined","Did not identify the full mammary target gene set"]},{"year":1997,"claim":"Showed STAT5 is activated by non-JAK receptor kinases, demonstrating direct phosphorylation by the insulin receptor and a requirement downstream of the erythropoietin receptor, broadening STAT5 inputs beyond cytokine JAKs.","evidence":"Yeast two-hybrid, in vitro kinase assay with purified IR domain, in vivo tissue phosphorylation; chimeric EpoR Y→F mutants and dominant-negative STAT5 in erythroleukemia cells","pmids":["9122188","9079629"],"confidence":"Medium","gaps":["Physiological weight of IR-direct phosphorylation versus JAK routes unresolved","EpoR-STAT5 erythroid role later shown largely Stat5b/redundant in vivo"]},{"year":1997,"claim":"Defined a specific STAT5A transcriptional target in immune signaling—the IL-2 receptor alpha chain—linking STAT5A loss to impaired low-affinity IL-2 proliferative responses.","evidence":"Stat5a knockout splenocytes, IL-2Ra expression analysis, and IL-2 dose-response proliferation assays","pmids":["9390692"],"confidence":"High","gaps":["Direct STAT5A occupancy of the IL-2Ra promoter not shown in this study","Redundancy with STAT5B not addressed"]},{"year":1998,"claim":"Dissected the activation mechanism, showing the JAK2 kinase domain is sufficient for STAT5 binding/phosphorylation, the SH2 residue R618 is required, and a single phosphotyrosine-SH2 contact drives dimerization but yields poorly DNA-binding dimers; also separated receptor-driven phosphorylation from nuclear translocation.","evidence":"Yeast reconstitution with integrated reporter, site-directed mutagenesis, stringent co-IP; PRLR phosphotyrosine mutant analysis with subcellular fractionation","pmids":["9575217","9516478"],"confidence":"Medium","gaps":["Structural detail of high-affinity DNA-binding dimer geometry not resolved","Identity of the nuclear translocation machinery downstream of PRLR Tyr382 unknown"]},{"year":2003,"claim":"Identified the phosphatases that terminate STAT5 signaling, establishing PTP1B and Shp-2 as direct, phospho-tyrosine-dependent STAT5 inactivators with functional consequences for transcription and nuclear localization.","evidence":"In vitro phosphatase assays, substrate-trapping co-precipitation, Shp-2-null cells, reporter assays (PTP1B reported 2000)","pmids":["10993888","12615921"],"confidence":"High","gaps":["Relative in vivo contributions of each phosphatase not ranked","Spatial site of dephosphorylation (cytoplasm vs nucleus) not fully defined"]},{"year":2003,"claim":"Expanded STAT5A's physiological and target-gene repertoire, defining a GAS element in the RANKL promoter, a STAT5A-sufficient adipogenic program, and a STAT5-GR association during differentiation.","evidence":"Dominant-negative JAK2/STAT5 with promoter mapping and COS7 reconstitution; ectopic STAT5A expression with adipogenesis markers and co-IP","pmids":["12952963","12540601"],"confidence":"Medium","gaps":["STAT5A vs STAT5B specificity in adipogenesis not mechanistically explained","Endogenous-context validation of RANKL regulation limited"]},{"year":2004,"claim":"Characterized regulatory and co-regulator partners that tune STAT5 activity, identifying STAP-2/BKS as a cytoplasmic negative regulator and (later) Runx1/2/3 as mutual transcriptional antagonists that retain STAT5 in the cytoplasm.","evidence":"Co-IP, domain mapping, intracellular staining, STAP-2-null thymocytes; Runx co-IP, fractionation, DNA-binding and CIS target gene readouts in Ba/F3 cells","pmids":["15611091","18296717"],"confidence":"Medium","gaps":["Quantitative impact of these regulators on physiological STAT5 outputs unclear","Single-lab co-IP evidence without reciprocal structural validation"]},{"year":2005,"claim":"Connected STAT5A to G-protein-coupled receptor signaling, showing Src-dependent tyrosine phosphorylation and direct binding to the mu-opioid receptor C-terminal YXXL motif.","evidence":"Co-IP and GST pulldown from brain/COS-7 extracts, MOR motif mutagenesis, Src inhibitor PP1, STAT-responsive reporter","pmids":["15857395"],"confidence":"Medium","gaps":["Downstream neuronal target genes not identified","Physiological relevance in vivo not established"]},{"year":2010,"claim":"Distinguished STAT5A's oncogenic from its physiological activity by showing serine phosphorylation at S725/S779 is required for leukemogenesis but dispensable for normal hematopoietic reconstitution.","evidence":"Serine-mutant complementation in Stat5-null cells and bone marrow transplantation leukemia model","pmids":["20508164"],"confidence":"High","gaps":["Kinase(s) responsible for S725/S779 phosphorylation not identified here","Mechanism by which serine phosphorylation alters target gene selection unresolved"]},{"year":2013,"claim":"Revealed a phosphorylation-independent function: unphosphorylated STAT5A binds HP1α to stabilize heterochromatin and repress cancer-associated genes, recasting the unphosphorylated pool as a tumor suppressor.","evidence":"Co-IP, transcriptome profiling, unphosphorylatable STAT5A mutant, and colon cancer xenografts; TMPRSS6 promoter ChIP also defined a direct iron-homeostasis target","pmids":["23733954","24376517"],"confidence":"Medium","gaps":["Genome-wide map of unphosphorylated STAT5A/HP1α sites incomplete","Switch dynamics between repressive and activating STAT5A pools not defined"]},{"year":2014,"claim":"Defined nuclear-entry and chromatin-cooperation mechanisms in transformed cells, showing PAK1 drives STAT5 nuclear translocation downstream of FAK-Rac1, and that persistent STAT5 activation recruits p53 to shared promoters.","evidence":"FAK/PAK1 inhibitors with in vivo leukemia models and fractionation; ChIP-seq co-localization of STAT5 and p53 with inhibition experiments","pmids":["25456130","24681953"],"confidence":"Medium","gaps":["Whether PAK1-driven translocation is import-receptor independent unknown","Functional consequence of STAT5-p53 co-occupancy on individual genes not dissected"]},{"year":2016,"claim":"Established that cell-type-specific autoregulatory and super-enhancers, decoded by in vivo CRISPR editing, amplify STAT5 levels and STAT5-dependent gene induction in mammary epithelium, explaining quantitative control of lactation genes.","evidence":"ChIP-seq, DNaseI hypersensitivity, combinatorial CRISPR/Cas9 mutagenesis in mice with transcriptome readouts; additional coactivator (HMGN2/HDAC6) and tissue-specific repressive roles (macrophage Cyp19a1, osteogenic DLX5) defined","pmids":["26446995","27376239","27358110","28606561","30429452"],"confidence":"High","gaps":["Hierarchy of trans-factors building the super-enhancer not fully resolved","Mechanistic basis of repressive vs activating enhancer engagement across tissues unclear"]},{"year":2017,"claim":"Showed O-GlcNAcylation is a required modification for STAT5 oncogenicity, promoting tyrosine phosphorylation, oligomerization, and transformation, adding a metabolism-linked PTM layer to STAT5 activation.","evidence":"O-GlcNAc-site mutagenesis with phosphorylation, oligomerization, and transformation assays in hematopoietic cells","pmids":["28074064"],"confidence":"Medium","gaps":["O-GlcNAc transferase responsible and modified residues' interplay with serine sites not defined","Effect on physiological (non-oncogenic) STAT5 signaling untested"]},{"year":2018,"claim":"Extended STAT5 function to DNA repair, demonstrating JAK2-dependent STAT5a/b induction of RAD51 is required for homologous recombination and confers radioresistance in prostate cancer.","evidence":"Comet, clonogenic, HR/NHEJ reporter assays, siRNA, xenografts, and patient-derived 3D explants; cardiomyocyte-specific Stat5 KO also defined an ischemic-preconditioning cardioprotective role","pmids":["29483142","29365089"],"confidence":"Medium","gaps":["Direct STAT5 occupancy of the RAD51 promoter not detailed here","Mechanism linking STAT5 to the apoptotic/HIF-1α program in cardiomyocytes incompletely mapped"]},{"year":2021,"claim":"Defined oligomerization-state and non-nuclear functions, showing N-domain tetramerization drives a specific cytokine output (CCL17) in autoimmunity and that a mitochondrial STAT5A pool disrupts the pyruvate dehydrogenase complex to enforce the Warburg effect.","evidence":"Tetramer-deficient N-domain knockin mice in EAE with rescue; STAT5A-PDC co-IP, PDC activity and metabolic profiling, hypoxia, and xenografts","pmids":["34934004","34148062"],"confidence":"Medium","gaps":["Import mechanism for mitochondrial STAT5A unknown","Structural basis distinguishing dimer vs tetramer target selection unresolved"]},{"year":2021,"claim":"Revealed post-transcriptional and feedback control of STAT5A itself, with YTHDF2-mediated m6A decay of STAT5A mRNA relieving STAT5A-dependent repression of the MAP2K2/ERK pathway, and pY694-STAT5 modulating NPM1/p53 stability.","evidence":"m6A-RIP-seq, RIP-PCR, ChIP-seq/qPCR and functional assays in myeloma; co-IP and ubiquitin-ligase/protein-stability assays for the NPM1-p53 axis","pmids":["35075244","28005077"],"confidence":"Medium","gaps":["Generality of STAT5A as an ERK-pathway repressor beyond myeloma unknown","Bidirectional STAT5-NPM1 regulation not validated in primary cells"]},{"year":2025,"claim":"Positioned the JAK2-STAT5 axis as a determinant of dendritic-cell immunogenicity restrained by STAT3, showing STAT3 degradation reprograms DCs toward STAT5-driven anti-tumor T cell priming.","evidence":"STAT3 PROTAC degraders, DC transcriptomics, T cell priming assays, in vivo tumor models","pmids":["40369063"],"confidence":"Medium","gaps":["Direct STAT5 target genes mediating DC immunogenicity not enumerated","Mechanism of STAT3 restraint over JAK2-STAT5 not biochemically defined"]},{"year":null,"claim":"How the same protein is partitioned among activating dimers/tetramers, repressive unphosphorylated heterochromatin complexes, and a metabolic mitochondrial pool—and what governs the switch between these states in a given cell—remains unresolved.","evidence":"No single study in the corpus integrates the competing STAT5A states or provides structural/quantitative models of their interconversion","pmids":[],"confidence":"Low","gaps":["No unified structural model of dimer/tetramer/monomer interconversion","Signals controlling mitochondrial import are unknown","Quantitative balance of nuclear-activating vs repressive pools per cell type undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,3,9,24,27,30,31,28]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[9,23,24,30,31,28]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[25]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[13,18,32]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[5,11,20,32]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[14]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[25]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[4,7,8,10]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[3,9,24,30,31]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[0,1,12,16,23,24,35]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[3,4,33,38]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[8,15,19,27]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[27]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[25,34]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[14]}],"complexes":[],"partners":["GR","JAK2","PTP1B","SHP2","RUNX1","STAP2","HP1A","NPM1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P42229","full_name":"Signal transducer and activator of transcription 5A","aliases":[],"length_aa":794,"mass_kda":90.6,"function":"Carries out a dual function: signal transduction and activation of transcription. Mediates cellular responses to the cytokine KITLG/SCF and other growth factors. Mediates cellular responses to ERBB4. May mediate cellular responses to activated FGFR1, FGFR2, FGFR3 and FGFR4. Binds to the GAS element and activates PRL-induced transcription. Regulates the expression of milk proteins during lactation","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/P42229/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/STAT5A","classification":"Not Classified","n_dependent_lines":127,"n_total_lines":1208,"dependency_fraction":0.10513245033112582},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/STAT5A","total_profiled":1310},"omim":[{"mim_id":"620485","title":"TUBULIN TYROSINE LIGASE-LIKE 13; TTLL13","url":"https://www.omim.org/entry/620485"},{"mim_id":"618796","title":"SAC3 DOMAIN-CONTAINING PROTEIN 1; SAC3D1","url":"https://www.omim.org/entry/618796"},{"mim_id":"618738","title":"TUBULIN TYROSINE LIGASE-LIKE 4; TTLL4","url":"https://www.omim.org/entry/618738"},{"mim_id":"617345","title":"ATP/GTP-BINDING PROTEIN-LIKE 2; AGBL2","url":"https://www.omim.org/entry/617345"},{"mim_id":"616012","title":"JAGUNAL HOMOLOG 1; JAGN1","url":"https://www.omim.org/entry/616012"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Cytosol","reliability":"Enhanced"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"adipose tissue","ntpm":74.1}],"url":"https://www.proteinatlas.org/search/STAT5A"},"hgnc":{"alias_symbol":["MGF"],"prev_symbol":["STAT5"]},"alphafold":{"accession":"P42229","domains":[{"cath_id":"1.10.532.10","chopping":"2-125","consensus_level":"high","plddt":89.4259,"start":2,"end":125},{"cath_id":"1.20.1050.20","chopping":"132-326","consensus_level":"high","plddt":92.8735,"start":132,"end":326},{"cath_id":"2.60.40.630","chopping":"337-472","consensus_level":"high","plddt":91.2815,"start":337,"end":472},{"cath_id":"1.10.238.10","chopping":"501-681","consensus_level":"medium","plddt":94.8383,"start":501,"end":681}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P42229","model_url":"https://alphafold.ebi.ac.uk/files/AF-P42229-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P42229-F1-predicted_aligned_error_v6.png","plddt_mean":85.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=STAT5A","jax_strain_url":"https://www.jax.org/strain/search?query=STAT5A"},"sequence":{"accession":"P42229","fasta_url":"https://rest.uniprot.org/uniprotkb/P42229.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P42229/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P42229"}},"corpus_meta":[{"pmid":"9630227","id":"PMC_9630227","title":"Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses.","date":"1998","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/9630227","citation_count":1020,"is_preprint":false},{"pmid":"9009201","id":"PMC_9009201","title":"Stat5a is mandatory for adult mammary gland development and lactogenesis.","date":"1997","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/9009201","citation_count":939,"is_preprint":false},{"pmid":"8878484","id":"PMC_8878484","title":"Functional interactions between Stat5 and the glucocorticoid receptor.","date":"1996","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8878484","citation_count":544,"is_preprint":false},{"pmid":"22271576","id":"PMC_22271576","title":"STAT5 is a potent negative regulator of TFH cell differentiation.","date":"2012","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22271576","citation_count":411,"is_preprint":false},{"pmid":"7568001","id":"PMC_7568001","title":"Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15.","date":"1995","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7568001","citation_count":317,"is_preprint":false},{"pmid":"18347089","id":"PMC_18347089","title":"Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B.","date":"2008","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/18347089","citation_count":287,"is_preprint":false},{"pmid":"10851055","id":"PMC_10851055","title":"The role of Stat5a and Stat5b in signaling by IL-2 family cytokines.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10851055","citation_count":281,"is_preprint":false},{"pmid":"27376239","id":"PMC_27376239","title":"Hierarchy within the mammary STAT5-driven Wap super-enhancer.","date":"2016","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27376239","citation_count":219,"is_preprint":false},{"pmid":"9390692","id":"PMC_9390692","title":"An indirect effect of Stat5a in IL-2-induced proliferation: a critical role for Stat5a in IL-2-mediated IL-2 receptor alpha chain induction.","date":"1997","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/9390692","citation_count":207,"is_preprint":false},{"pmid":"29728695","id":"PMC_29728695","title":"Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer.","date":"2018","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/29728695","citation_count":204,"is_preprint":false},{"pmid":"10743504","id":"PMC_10743504","title":"Stat5a and Stat5b: fraternal twins of signal transduction and transcriptional activation.","date":"1999","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/10743504","citation_count":200,"is_preprint":false},{"pmid":"17356133","id":"PMC_17356133","title":"Activation mechanisms of STAT5 by oncogenic Flt3-ITD.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17356133","citation_count":176,"is_preprint":false},{"pmid":"26716518","id":"PMC_26716518","title":"STAT5 in Cancer and Immunity.","date":"2015","source":"Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research","url":"https://pubmed.ncbi.nlm.nih.gov/26716518","citation_count":139,"is_preprint":false},{"pmid":"10993888","id":"PMC_10993888","title":"A cytosolic protein-tyrosine phosphatase PTP1B specifically dephosphorylates and deactivates prolactin-activated STAT5a and STAT5b.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10993888","citation_count":139,"is_preprint":false},{"pmid":"29472718","id":"PMC_29472718","title":"Pharmacologic inhibition of STAT5 in acute myeloid leukemia.","date":"2018","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/29472718","citation_count":133,"is_preprint":false},{"pmid":"12714518","id":"PMC_12714518","title":"Stat5 expression is critical for mast cell development and survival.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12714518","citation_count":126,"is_preprint":false},{"pmid":"19491198","id":"PMC_19491198","title":"Reciprocal effects of STAT5 and STAT3 in breast cancer.","date":"2009","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/19491198","citation_count":115,"is_preprint":false},{"pmid":"15067053","id":"PMC_15067053","title":"STAT5 activation underlies IL7 receptor-dependent B cell development.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15067053","citation_count":114,"is_preprint":false},{"pmid":"9122188","id":"PMC_9122188","title":"Stat5 is a physiological substrate of the insulin receptor.","date":"1997","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9122188","citation_count":113,"is_preprint":false},{"pmid":"20969928","id":"PMC_20969928","title":"The role of Stat5 transcription factors as tumor suppressors or oncogenes.","date":"2010","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/20969928","citation_count":108,"is_preprint":false},{"pmid":"12952963","id":"PMC_12952963","title":"Receptor activator of NF-kappaB ligand induction via Jak2 and Stat5a in mammary epithelial cells.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12952963","citation_count":98,"is_preprint":false},{"pmid":"12540601","id":"PMC_12540601","title":"STAT5A promotes adipogenesis in nonprecursor cells and associates with the glucocorticoid receptor during adipocyte differentiation.","date":"2003","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/12540601","citation_count":96,"is_preprint":false},{"pmid":"12615921","id":"PMC_12615921","title":"Identification of Shp-2 as a Stat5A phosphatase.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12615921","citation_count":94,"is_preprint":false},{"pmid":"18218766","id":"PMC_18218766","title":"Mutations in the STAT5A gene are associated with embryonic survival and milk composition in cattle.","date":"2008","source":"Journal of dairy science","url":"https://pubmed.ncbi.nlm.nih.gov/18218766","citation_count":93,"is_preprint":false},{"pmid":"31557897","id":"PMC_31557897","title":"STAT3 and STAT5 Activation in Solid Cancers.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31557897","citation_count":92,"is_preprint":false},{"pmid":"10851049","id":"PMC_10851049","title":"Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruptions in mice.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10851049","citation_count":91,"is_preprint":false},{"pmid":"32094348","id":"PMC_32094348","title":"Suppressing STAT5 signaling affects osteosarcoma growth and stemness.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32094348","citation_count":79,"is_preprint":false},{"pmid":"32872372","id":"PMC_32872372","title":"Involvement of STAT5 in Oncogenesis.","date":"2020","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/32872372","citation_count":77,"is_preprint":false},{"pmid":"9079629","id":"PMC_9079629","title":"STAT5 activation correlates with erythropoietin receptor-mediated erythroid differentiation of an erythroleukemia cell line.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9079629","citation_count":77,"is_preprint":false},{"pmid":"31817042","id":"PMC_31817042","title":"Direct Targeting Options for STAT3 and STAT5 in Cancer.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31817042","citation_count":76,"is_preprint":false},{"pmid":"24412367","id":"PMC_24412367","title":"Critical role for mast cell Stat5 activity in skin inflammation.","date":"2014","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/24412367","citation_count":76,"is_preprint":false},{"pmid":"15382041","id":"PMC_15382041","title":"Deregulation of Stat5 expression and activation causes mammary tumors in transgenic mice.","date":"2004","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15382041","citation_count":74,"is_preprint":false},{"pmid":"18779318","id":"PMC_18779318","title":"Maximal STAT5-induced proliferation and self-renewal at intermediate STAT5 activity levels.","date":"2008","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18779318","citation_count":72,"is_preprint":false},{"pmid":"11290598","id":"PMC_11290598","title":"Stat5a regulates T helper cell differentiation by several distinct mechanisms.","date":"2001","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11290598","citation_count":69,"is_preprint":false},{"pmid":"9516478","id":"PMC_9516478","title":"Prolactin receptor regulates Stat5 tyrosine phosphorylation and nuclear translocation by two separate pathways.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9516478","citation_count":67,"is_preprint":false},{"pmid":"23733954","id":"PMC_23733954","title":"Unphosphorylated STAT5A stabilizes heterochromatin and suppresses tumor growth.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23733954","citation_count":65,"is_preprint":false},{"pmid":"31963765","id":"PMC_31963765","title":"Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31963765","citation_count":62,"is_preprint":false},{"pmid":"20227268","id":"PMC_20227268","title":"STAT5 in B cell development and leukemia.","date":"2010","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20227268","citation_count":61,"is_preprint":false},{"pmid":"17485261","id":"PMC_17485261","title":"STAT5 signaling in normal and pathologic hematopoiesis.","date":"2007","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/17485261","citation_count":61,"is_preprint":false},{"pmid":"19747364","id":"PMC_19747364","title":"Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms.","date":"2009","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/19747364","citation_count":61,"is_preprint":false},{"pmid":"34281163","id":"PMC_34281163","title":"STAT5 as a Key Protein of Erythropoietin Signalization.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34281163","citation_count":59,"is_preprint":false},{"pmid":"28074064","id":"PMC_28074064","title":"O-GlcNAcylation of STAT5 controls tyrosine phosphorylation and oncogenic transcription in STAT5-dependent malignancies.","date":"2017","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/28074064","citation_count":54,"is_preprint":false},{"pmid":"31717342","id":"PMC_31717342","title":"Structural Implications of STAT3 and STAT5 SH2 Domain Mutations.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31717342","citation_count":53,"is_preprint":false},{"pmid":"16920984","id":"PMC_16920984","title":"Stat5 expression is required for IgE-mediated mast cell function.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16920984","citation_count":53,"is_preprint":false},{"pmid":"25456130","id":"PMC_25456130","title":"Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis.","date":"2014","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/25456130","citation_count":53,"is_preprint":false},{"pmid":"15611091","id":"PMC_15611091","title":"Physical and functional interactions between STAP-2/BKS and STAT5.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15611091","citation_count":50,"is_preprint":false},{"pmid":"20508164","id":"PMC_20508164","title":"Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20508164","citation_count":50,"is_preprint":false},{"pmid":"17379095","id":"PMC_17379095","title":"Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.","date":"2007","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/17379095","citation_count":49,"is_preprint":false},{"pmid":"29483142","id":"PMC_29483142","title":"STAT5A/B Blockade Sensitizes Prostate Cancer to Radiation through Inhibition of RAD51 and DNA Repair.","date":"2018","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/29483142","citation_count":48,"is_preprint":false},{"pmid":"26446995","id":"PMC_26446995","title":"An autoregulatory enhancer controls mammary-specific STAT5 functions.","date":"2015","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/26446995","citation_count":48,"is_preprint":false},{"pmid":"29724813","id":"PMC_29724813","title":"EGFRvIII-Stat5 Signaling Enhances Glioblastoma Cell Migration and Survival.","date":"2018","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/29724813","citation_count":46,"is_preprint":false},{"pmid":"16883580","id":"PMC_16883580","title":"Stat5 in the mammary gland: controlling normal development and cancer.","date":"2006","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/16883580","citation_count":44,"is_preprint":false},{"pmid":"28287479","id":"PMC_28287479","title":"STAT5-Interacting Proteins: A Synopsis of Proteins that Regulate STAT5 Activity.","date":"2017","source":"Biology","url":"https://pubmed.ncbi.nlm.nih.gov/28287479","citation_count":43,"is_preprint":false},{"pmid":"23660011","id":"PMC_23660011","title":"STAT5A/B gene locus undergoes amplification during human prostate cancer progression.","date":"2013","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23660011","citation_count":43,"is_preprint":false},{"pmid":"18508657","id":"PMC_18508657","title":"The different functions of Stat5 and chromatin alteration through Stat5 proteins.","date":"2008","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/18508657","citation_count":41,"is_preprint":false},{"pmid":"15870688","id":"PMC_15870688","title":"Haploinsufficiency identifies STAT5 as a modifier of IL-7-induced lymphomas.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15870688","citation_count":41,"is_preprint":false},{"pmid":"40369063","id":"PMC_40369063","title":"STAT5 and STAT3 balance shapes dendritic cell function and tumour immunity.","date":"2025","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/40369063","citation_count":40,"is_preprint":false},{"pmid":"9575217","id":"PMC_9575217","title":"Jak2-Stat5 interactions analyzed in yeast.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9575217","citation_count":40,"is_preprint":false},{"pmid":"28163905","id":"PMC_28163905","title":"STAT5 and CD4 + T Cell Immunity.","date":"2017","source":"F1000Research","url":"https://pubmed.ncbi.nlm.nih.gov/28163905","citation_count":39,"is_preprint":false},{"pmid":"9442383","id":"PMC_9442383","title":"Mechanism of interaction between the glucocorticoid receptor and Stat5: role of DNA-binding.","date":"1997","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/9442383","citation_count":39,"is_preprint":false},{"pmid":"31024554","id":"PMC_31024554","title":"Evaluating STAT5 Phosphorylation as a Mean to Assess T Cell Proliferation.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31024554","citation_count":38,"is_preprint":false},{"pmid":"35075244","id":"PMC_35075244","title":"YTHDF2 promotes multiple myeloma cell proliferation via STAT5A/MAP2K2/p-ERK axis.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/35075244","citation_count":37,"is_preprint":false},{"pmid":"29365089","id":"PMC_29365089","title":"Stat5-dependent cardioprotection in late remote ischaemia preconditioning.","date":"2018","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/29365089","citation_count":37,"is_preprint":false},{"pmid":"9374508","id":"PMC_9374508","title":"Cytokine receptor-independent, constitutively active variants of STAT5.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9374508","citation_count":37,"is_preprint":false},{"pmid":"18296717","id":"PMC_18296717","title":"Physical and functional interactions between STAT5 and Runx transcription factors.","date":"2008","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18296717","citation_count":36,"is_preprint":false},{"pmid":"31123029","id":"PMC_31123029","title":"High activation of STAT5A drives peripheral T-cell lymphoma and leukemia.","date":"2020","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/31123029","citation_count":35,"is_preprint":false},{"pmid":"29460051","id":"PMC_29460051","title":"Brain STAT5 signaling modulates learning and memory formation.","date":"2018","source":"Brain structure & function","url":"https://pubmed.ncbi.nlm.nih.gov/29460051","citation_count":35,"is_preprint":false},{"pmid":"27358110","id":"PMC_27358110","title":"HDAC6 Deacetylates HMGN2 to Regulate Stat5a Activity and Breast Cancer Growth.","date":"2016","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/27358110","citation_count":35,"is_preprint":false},{"pmid":"31158467","id":"PMC_31158467","title":"The RAGE/STAT5/autophagy axis regulates senescence in mesangial cells.","date":"2019","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/31158467","citation_count":34,"is_preprint":false},{"pmid":"24681953","id":"PMC_24681953","title":"Persistent STAT5 activation in myeloid neoplasms recruits p53 into gene regulation.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24681953","citation_count":34,"is_preprint":false},{"pmid":"19011510","id":"PMC_19011510","title":"STAT5 contributes to antiapoptosis in melanoma.","date":"2008","source":"Melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/19011510","citation_count":33,"is_preprint":false},{"pmid":"26848862","id":"PMC_26848862","title":"FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26848862","citation_count":32,"is_preprint":false},{"pmid":"9694697","id":"PMC_9694697","title":"Erythropoietin receptor and STAT5-specific pathways promote SKT6 cell hemoglobinization.","date":"1998","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9694697","citation_count":31,"is_preprint":false},{"pmid":"24498540","id":"PMC_24498540","title":"STAT5 in hematopoietic stem cell biology and transplantation.","date":"2013","source":"JAK-STAT","url":"https://pubmed.ncbi.nlm.nih.gov/24498540","citation_count":30,"is_preprint":false},{"pmid":"34148062","id":"PMC_34148062","title":"Mitochondrial STAT5A promotes metabolic remodeling and the Warburg effect by inactivating the pyruvate dehydrogenase complex.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/34148062","citation_count":30,"is_preprint":false},{"pmid":"36917143","id":"PMC_36917143","title":"Batf stabilizes Th17 cell development via impaired Stat5 recruitment of Ets1-Runx1 complexes.","date":"2023","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/36917143","citation_count":29,"is_preprint":false},{"pmid":"14637146","id":"PMC_14637146","title":"LMW-PTP associates and dephosphorylates STAT5 interacting with its C-terminal domain.","date":"2003","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/14637146","citation_count":29,"is_preprint":false},{"pmid":"16375697","id":"PMC_16375697","title":"Signal transducer and activator of transcription 5 (STAT5), a crucial regulator of immune and cancer cells.","date":"2005","source":"Current drug targets. Immune, endocrine and metabolic disorders","url":"https://pubmed.ncbi.nlm.nih.gov/16375697","citation_count":28,"is_preprint":false},{"pmid":"34934004","id":"PMC_34934004","title":"Tetramerization of STAT5 promotes autoimmune-mediated neuroinflammation.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/34934004","citation_count":27,"is_preprint":false},{"pmid":"28005077","id":"PMC_28005077","title":"Phosphorylated STAT5 regulates p53 expression via BRCA1/BARD1-NPM1 and MDM2.","date":"2016","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/28005077","citation_count":27,"is_preprint":false},{"pmid":"24836440","id":"PMC_24836440","title":"BCR-ABL affects STAT5A and STAT5B differentially.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24836440","citation_count":27,"is_preprint":false},{"pmid":"29246863","id":"PMC_29246863","title":"Essential roles of stat5.1/stat5b in controlling fish somatic growth.","date":"2017","source":"Journal of genetics and genomics = Yi chuan xue bao","url":"https://pubmed.ncbi.nlm.nih.gov/29246863","citation_count":27,"is_preprint":false},{"pmid":"31494175","id":"PMC_31494175","title":"Growth hormone/STAT5 signaling in proopiomelanocortin neurons regulates glucoprivic hyperphagia.","date":"2019","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/31494175","citation_count":27,"is_preprint":false},{"pmid":"25472543","id":"PMC_25472543","title":"A positive feedback loop between prolactin and STAT5 promotes angiogenesis.","date":"2015","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/25472543","citation_count":26,"is_preprint":false},{"pmid":"29579399","id":"PMC_29579399","title":"GSK3-activated STAT5 regulates expression of SFRPs to modulate adipogenesis.","date":"2018","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/29579399","citation_count":26,"is_preprint":false},{"pmid":"30429452","id":"PMC_30429452","title":"Inhibition of STAT5A promotes osteogenesis by DLX5 regulation.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30429452","citation_count":26,"is_preprint":false},{"pmid":"15857395","id":"PMC_15857395","title":"STAT5A interacts with and is phosphorylated upon activation of the mu-opioid receptor.","date":"2005","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15857395","citation_count":26,"is_preprint":false},{"pmid":"37106040","id":"PMC_37106040","title":"Dynamic chromatin accessibility licenses STAT5- and STAT6-dependent innate-like function of TH9 cells to promote allergic inflammation.","date":"2023","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37106040","citation_count":25,"is_preprint":false},{"pmid":"27694626","id":"PMC_27694626","title":"Differential cytokine sensitivities of STAT5-dependent enhancers rely on Stat5 autoregulation.","date":"2016","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/27694626","citation_count":24,"is_preprint":false},{"pmid":"34078871","id":"PMC_34078871","title":"Disruption of STAT5A and NMI signaling axis leads to ISG20-driven metastatic mammary tumors.","date":"2021","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/34078871","citation_count":24,"is_preprint":false},{"pmid":"24416653","id":"PMC_24416653","title":"STAT5 acetylation: Mechanisms and consequences for immunological control and leukemogenesis.","date":"2013","source":"JAK-STAT","url":"https://pubmed.ncbi.nlm.nih.gov/24416653","citation_count":23,"is_preprint":false},{"pmid":"12217382","id":"PMC_12217382","title":"Stat5: an essential regulator of mast cell biology.","date":"2002","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12217382","citation_count":23,"is_preprint":false},{"pmid":"30154155","id":"PMC_30154155","title":"Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia.","date":"2018","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/30154155","citation_count":23,"is_preprint":false},{"pmid":"33482575","id":"PMC_33482575","title":"A centric view of JAK/STAT5 in intestinal homeostasis, infection, and inflammation.","date":"2021","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/33482575","citation_count":23,"is_preprint":false},{"pmid":"27118133","id":"PMC_27118133","title":"Brain STAT5 signaling and behavioral control.","date":"2016","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/27118133","citation_count":23,"is_preprint":false},{"pmid":"34336684","id":"PMC_34336684","title":"STAT5a Confers Doxorubicin Resistance to Breast Cancer by Regulating ABCB1.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34336684","citation_count":23,"is_preprint":false},{"pmid":"30376668","id":"PMC_30376668","title":"JAK2/STAT5 Pathway Mediates Prolactin-Induced Apoptosis of Lactotropes.","date":"2018","source":"Neuroendocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/30376668","citation_count":22,"is_preprint":false},{"pmid":"24376517","id":"PMC_24376517","title":"Inflammation regulates TMPRSS6 expression via STAT5.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24376517","citation_count":22,"is_preprint":false},{"pmid":"31646566","id":"PMC_31646566","title":"STAT5A reprograms fatty acid metabolism and promotes tumorigenesis of gastric cancer cells.","date":"2019","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31646566","citation_count":22,"is_preprint":false},{"pmid":"28606561","id":"PMC_28606561","title":"STAT5 deletion in macrophages alters ductal elongation and branching during mammary gland development.","date":"2017","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/28606561","citation_count":22,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":46774,"output_tokens":9446,"usd":0.141006,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19732,"output_tokens":7151,"usd":0.138717,"stage2_stop_reason":"end_turn"},"total_usd":0.279723,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"Stat5a is the principal and obligate mediator of prolactin-induced mammary lobuloalveolar development and lactogenesis; targeted deletion of Stat5a in mice abolishes terminal differentiation of mammary epithelium and lactation, despite Stat5b having 96% similarity and a superimposable expression pattern.\",\n      \"method\": \"Gene targeting (knockout mice), mammary gland histology, lactation phenotyping\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic KO with defined cellular phenotype, replicated across multiple subsequent studies, clear non-redundancy with Stat5b established by direct comparison\",\n      \"pmids\": [\"9009201\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Stat5a and Stat5b have essential but often redundant roles in cytokine responses mediated by growth hormone and prolactin; individual and double-knockout mice show that Stat5a is specifically required for prolactin-driven mammary responses while erythropoietin responses are largely unaffected.\",\n      \"method\": \"Individual and combined gene targeting (knockout mice), cytokine response phenotyping\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with defined phenotypic readouts, broadly replicated, multi-cytokine epistasis established\",\n      \"pmids\": [\"9630227\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"STAT5 forms a physical complex with the glucocorticoid receptor (GR); this complex binds DNA independently of classical GRE sequences and enables GR to act as a transcriptional co-activator enhancing STAT5-dependent transcription, while simultaneously diminishing GRE-driven glucocorticoid responses.\",\n      \"method\": \"Co-immunoprecipitation, DNA-binding assays, transcriptional reporter assays, transfection in mammalian cells\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP plus functional reporter assays, replicated by independent lab (Lechner 1997)\",\n      \"pmids\": [\"8878484\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Stat5a is activated by IL-2 and is specifically required for IL-2-induced upregulation of the IL-2 receptor alpha chain (IL-2Rα/CD25); defective IL-2Rα expression in Stat5a-/- splenocytes leads to markedly decreased proliferative responses to low-affinity IL-2 concentrations.\",\n      \"method\": \"Stat5a knockout mice, splenocyte proliferation assays, IL-2Rα expression analysis, IL-2 dose-response\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic KO with specific mechanistic readout (receptor expression) and dose-response validation\",\n      \"pmids\": [\"9390692\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"IL-2 and IL-15 rapidly induce tyrosine phosphorylation of STAT5 (and STAT3) and activate STAT5-containing DNA-binding complexes in human T cells; JAK1 and JAK3 are co-phosphorylated, establishing STAT5 as downstream of the JAK1/JAK3 axis for IL-2 family cytokines.\",\n      \"method\": \"Tyrosine phosphorylation assays, electrophoretic mobility shift assay (EMSA), immunoprecipitation of JAKs in human T cells\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (phosphorylation + DNA binding + kinase IP), single lab\",\n      \"pmids\": [\"7568001\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"PTP1B specifically dephosphorylates and inactivates prolactin-activated STAT5a and STAT5b; overexpression of PTP1B inhibits nuclear translocation of STAT5 and suppresses PRL-dependent beta-casein gene transcription; substrate-trapping PTP1B mutants co-precipitate endogenous tyrosine-phosphorylated STAT5.\",\n      \"method\": \"In vitro phosphatase assay, overexpression in COS7 and COMMA-1D mammary cells, retrovirus-mediated overexpression, substrate-trapping co-precipitation, reporter gene assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro enzymatic assay plus substrate-trapping co-precipitation plus functional transcriptional readout, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"10993888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Shp-2 (but not Shp-1) specifically interacts with tyrosine-phosphorylated STAT5A in vivo, accelerates its dephosphorylation, and dephosphorylation of STAT5A is dramatically delayed in Shp-2-deficient cells; interaction is phospho-tyrosine-dependent.\",\n      \"method\": \"Phosphopeptide affinity purification, co-immunoprecipitation, Shp-2-deficient cells, phosphatase assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — biochemical purification plus co-IP plus genetic null cells, single lab with multiple orthogonal approaches\",\n      \"pmids\": [\"12615921\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The insulin receptor (IR) directly phosphorylates STAT5 in vitro; insulin stimulates tyrosine phosphorylation and DNA-binding activity of STAT5 in liver, skeletal muscle, and adipose tissue; STAT5b C-terminal domain interacts with the IR cytoplasmic domain identified by yeast two-hybrid.\",\n      \"method\": \"Yeast two-hybrid, in vitro kinase assay with purified IR kinase domain, in vivo tyrosine phosphorylation, EMSA on tissue extracts\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution kinase assay plus yeast two-hybrid plus in vivo tissue validation, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"9122188\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Oncogenic Flt3-ITD directly phosphorylates and activates STAT5 independently of Src family kinases and JAK kinases; demonstrated by in vitro kinase assay showing STAT5 as direct Flt3 substrate, and by SOCS1 overexpression (which inhibits IL-3- but not Flt3-ITD-mediated STAT5 activation).\",\n      \"method\": \"In vitro kinase assay, small-molecule kinase inhibitors, Src-deficient cell lines, JAK2/Tyk2-deficient cells, SOCS1 overexpression\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro kinase reconstitution plus multiple genetic/pharmacologic epistasis approaches, single lab\",\n      \"pmids\": [\"17356133\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"JAK2 and STAT5a are essential for prolactin-induced RANKL expression in mammary epithelial cells; identified a GAS element in the RANKL promoter conferring PRL responsiveness, demonstrated by dominant-negative mutants of JAK2 and STAT5, and reconstitution of the JAK2/STAT5 pathway in COS7 cells.\",\n      \"method\": \"Dominant-negative mutants, luciferase reporter assay, pathway reconstitution in COS7 cells, promoter deletion analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — dominant-negative epistasis plus reconstitution plus promoter mapping, single lab\",\n      \"pmids\": [\"12952963\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"JAK2 kinase domain is sufficient for interaction with and phosphorylation of STAT5; the STAT5 SH2 domain R618K mutation abolishes JAK2-mediated phosphorylation; a single phosphotyrosine-SH2 interaction is sufficient for STAT5 dimerization but produces dimers that bind DNA very inefficiently; C-terminal deletion causes STAT5 hyperphosphorylation.\",\n      \"method\": \"Yeast-based expression system with integrated reporter, site-directed mutagenesis, co-immunoprecipitation under stringent conditions, deletion mutant analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — mutagenesis plus yeast reconstitution system with rigorous controls, single lab\",\n      \"pmids\": [\"9575217\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Prolactin receptor (PRLR) regulates STAT5 tyrosine phosphorylation and nuclear translocation by two separate mechanisms: phosphorylation is independent of PRLR phosphotyrosines, whereas nuclear translocation specifically requires the C-terminal tyrosine of the PRLR Nb2 form (Tyr382).\",\n      \"method\": \"PRLR phosphotyrosine mutant analysis, overexpression of natural and mutant PRLR forms in HC11 and 293-LA cells, subcellular fractionation, DNA-binding assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — site-directed mutagenesis of receptor plus nuclear translocation readout, single lab with two cell systems\",\n      \"pmids\": [\"9516478\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"STAT5A, but not STAT5B alone, is sufficient to promote adipogenesis in non-precursor fibroblast cell lines and induces expression of early and late adipogenic markers; STAT5A physically associates with the glucocorticoid receptor during adipogenesis in a regulated manner.\",\n      \"method\": \"Ectopic expression in BALB/c and NIH-3T3 cells, morphological and biochemical adipogenesis markers, co-immunoprecipitation during differentiation\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — ectopic expression with multiple readouts plus co-IP, single lab\",\n      \"pmids\": [\"12540601\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Physical interaction between STAP-2/BKS and STAT5 occurs via the PH- and SH2-like domains of STAP-2/BKS binding the C-terminal region of STAT5; STAP-2/BKS co-localizes with STAT5 in the cytoplasm of resting cells and dissociates upon STAT5 phosphorylation; overexpression of STAP-2/BKS diminishes cytokine-induced STAT5 tyrosine phosphorylation and transcriptional activation.\",\n      \"method\": \"Co-immunoprecipitation, intracellular staining, mutational analysis, STAP-2/BKS-deficient mice thymocytes, overexpression assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — co-IP plus mutational domain mapping plus functional readout plus KO mice, single lab\",\n      \"pmids\": [\"15611091\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Unphosphorylated STAT5A binds to heterochromatin protein 1α (HP1α) and stabilizes heterochromatin; expression of unphosphorylatable STAT5A produces similar global gene repression as HP1α overexpression, with most co-repressed genes implicated in cancer development; expressing unphosphorylated STAT5A or HP1α inhibits colon cancer xenograft growth.\",\n      \"method\": \"Co-immunoprecipitation, transcriptome profiling, mouse xenograft models, unphosphorylatable STAT5A mutant expression\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus transcriptome plus in vivo xenograft, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"23733954\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Serine phosphorylation of Stat5a at residues 725 and 779 is a prerequisite for oncogenic/leukemogenic transformation; mutating these serines abolishes the leukemogenic potential of constitutively active Stat5a in bone marrow transplants, while normal hematopoietic reconstitution functions are preserved.\",\n      \"method\": \"Site-directed mutagenesis of Stat5a serine residues, genetic complementation in Stat5-null cells, in vivo bone marrow transplantation leukemia model\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — mutagenesis plus in vivo reconstitution in primary null cells plus transplantation model, single lab but multiple orthogonal approaches\",\n      \"pmids\": [\"20508164\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"STAT5 activation correlates with and is required for erythropoietin receptor (EpoR)-mediated erythroid differentiation; EpoR Tyr343 or Tyr401 independently activates STAT5 and induces erythroid differentiation; dominant-negative STAT5 suppresses EPO-dependent erythroid differentiation.\",\n      \"method\": \"Chimeric EpoR mutants with Y→F substitutions, dominant-negative STAT5 overexpression, globin expression assay in erythroleukemia ELM-I-1 cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — receptor mutagenesis plus dominant-negative epistasis plus functional differentiation readout, single lab\",\n      \"pmids\": [\"9079629\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"LMW-PTP associates with and dephosphorylates STAT5 in megakaryocytic cells; interaction involves the C-terminal domain of STAT5 (not exclusively the phosphotyrosine-active site interaction), identifying LMW-PTP as a STAT5 phosphatase.\",\n      \"method\": \"Co-immunoprecipitation in DAMI megakaryocytic cells, phosphatase assay, domain mapping\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single co-IP/phosphatase assay, single lab, single method set\",\n      \"pmids\": [\"14637146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"STAT5 physically interacts with Runx1, Runx2, and Runx3 via its DNA-binding domain and α-helix loop; STAT5 retains Runx proteins in the cytoplasm; STAT5-Runx interaction mutually inhibits transcriptional activity of both, and Runx proteins inhibit STAT5 DNA-binding activity.\",\n      \"method\": \"Co-immunoprecipitation, reporter assay, subcellular localization (nuclear/cytoplasmic fractionation), DNA-binding assay, endogenous target gene (CIS) expression in Ba/F3 cells\",\n      \"journal\": \"Journal of biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — co-IP plus functional reporter plus localization plus endogenous target gene, single lab with multiple methods\",\n      \"pmids\": [\"18296717\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"O-GlcNAcylation of STAT5 promotes its tyrosine phosphorylation, oligomerization, and oncogenic transactivation; a hyperactive STAT5 mutant lacking O-GlcNAcylation shows decreased tyrosine phosphorylation, oligomerization, transactivation potential, and complete loss of oncogenic transformation capacity.\",\n      \"method\": \"O-GlcNAcylation site mutagenesis, tyrosine phosphorylation assays, oligomerization assays, oncogenic transformation assays in hematopoietic cells\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — mutagenesis plus multiple biochemical readouts plus functional transformation assay, single lab\",\n      \"pmids\": [\"28074064\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"In oncogenic FLT3/KIT-driven leukemic cells, FAK activates Rac1 via RacGEF Tiam1, which activates PAK1; PAK1 promotes nuclear translocation of Stat5; pharmacologic inhibition of PAK1 inhibits Stat5 nuclear translocation and prolongs survival of leukemic mice.\",\n      \"method\": \"FAK/PAK1 pharmacologic inhibitors, in vivo leukemia mouse models, subcellular fractionation, survival analysis of leukemic mice\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo epistasis with inhibitors plus nuclear translocation readout, single lab\",\n      \"pmids\": [\"25456130\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"HDAC6 deacetylates the STAT5a coactivator HMGN2 at lysine K2; deacetylated HMGN2 promotes STAT5a-mediated transcription and breast cancer growth; HDAC6 inhibition enhances HMGN2 acetylation with concomitant reduction in STAT5a-mediated signaling.\",\n      \"method\": \"HDAC6 inhibition in vitro and in vivo, acetylation site identification (K2), co-immunoprecipitation, chromatin assays, breast cancer xenograft models\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical acetylation site identification plus functional in vitro/in vivo readout, single lab\",\n      \"pmids\": [\"27358110\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Persistent (but not transient) STAT5 activation recruits p53 to chromatin; genome-wide ChIP shows STAT5 and p53 co-localize at 463 proximal promoter positions in transformed hematopoietic cells; chromatin binding of p53 at these sites is dependent on persistent STAT5 activation.\",\n      \"method\": \"ChIP-seq, ChIP, reporter assay, STAT5 and p53 inhibition, patient MPN platelet gene expression\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq genome-wide plus functional inhibition readout, single lab\",\n      \"pmids\": [\"24681953\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"A mammary-specific intergenic enhancer between the Stat5a and Stat5b loci contains STAT5-binding motifs and drives positive autoregulatory feedback; CRISPR/Cas9 deletion of STAT5-binding sites reduces Stat5 levels in mammary epithelium by ~80% and correspondingly reduces STAT5-dependent gene expression.\",\n      \"method\": \"ChIP-seq, DNaseI hypersensitivity, CRISPR/Cas9 genome editing in mice, transcriptome analysis\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — CRISPR-based in vivo genome editing with defined molecular and transcriptomic phenotype, supported by ChIP-seq\",\n      \"pmids\": [\"26446995\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"The mammary Wap super-enhancer contains a functional hierarchy of STAT5A-binding sites; combinatorial CRISPR/Cas9 mutation of all constituent enhancers is required for the full ~1000-fold induction of Wap expression during pregnancy; disabling STAT5, NFIB, and ELF5 binding sites in the proximal enhancer incapacitates the entire super-enhancer.\",\n      \"method\": \"ChIP-seq (STAT5A, GR, H3K27ac, MED1), CRISPR/Cas9 combinatorial mutagenesis in mice, reporter assays\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — genome-wide ChIP-seq plus combinatorial CRISPR in vivo mutagenesis with specific phenotypic and transcriptional readouts\",\n      \"pmids\": [\"27376239\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"A mitochondrial fraction of STAT5A interacts with the pyruvate dehydrogenase complex (PDC), disrupts PDC integrity, inhibits PDC activity, and promotes the Warburg effect; mitochondrial translocation of STAT5A increases under hypoxic conditions and promotes tumor growth in vivo.\",\n      \"method\": \"Co-immunoprecipitation of STAT5A with PDC subunits, PDC activity assays, glycolysis/OXPHOS metabolic profiling, hypoxia treatment, xenograft tumor models\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus enzymatic activity assay plus metabolic readout plus in vivo, single lab\",\n      \"pmids\": [\"34148062\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"STAT5A physically interacts with and is tyrosine-phosphorylated upon activation of the mu-opioid receptor (MOR) via a Src-dependent mechanism; the YXXL motif (aa 336-339) in the MOR C-terminal tail is required for STAT5A binding; Src inhibitor PP1 abolishes opioid-dependent STAT5A phosphorylation.\",\n      \"method\": \"Co-immunoprecipitation, GST pulldown from rat brain/COS-7 extracts, site-directed mutagenesis of MOR YXXL motif, Src inhibitor PP1, STAT-responsive reporter gene\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — co-IP plus GST pulldown plus mutagenesis plus reporter assay, single lab\",\n      \"pmids\": [\"15857395\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"STAT5a/b is required for RAD51 expression and homologous recombination (HR) DNA repair in prostate cancer via JAK2-dependent induction of Rad51 mRNA; genetic knockdown of STAT5a/b suppresses HR but not NHEJ, and pharmacologic STAT5 inhibition sensitizes prostate cancer to radiation.\",\n      \"method\": \"Comet assay, clonogenic survival assay, HR/NHEJ reporter assays, RAD51 expression analysis, STAT5a/b siRNA knockdown, xenograft in vivo models, patient-derived 3D explant cultures\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal DNA repair assays plus in vivo xenograft, single lab\",\n      \"pmids\": [\"29483142\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"STAT5A negatively regulates MAP2K2 transcription by occupying its promoter, thereby decreasing ERK phosphorylation; YTHDF2 m6A reader promotes STAT5A mRNA degradation by binding its m6A modification site, thus relieving STAT5A-mediated suppression of the MAP2K2/ERK pathway in multiple myeloma.\",\n      \"method\": \"m6A-RIP-seq, RIP-PCR, ChIP-seq, ChIP-qPCR, siRNA knockdown/overexpression, in vitro and in vivo proliferation assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq plus m6A-RIP-seq plus functional readout, single lab\",\n      \"pmids\": [\"35075244\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Cardiomyocyte-specific Stat5 knockout abolishes late remote ischemic preconditioning (RIPC)-induced cardioprotection against myocardial I/R injury; RIPC requires Stat5 to activate anti-apoptotic signaling (Bcl-2, Bcl-xL), suppress cytochrome c/caspase-3, and activate HIF-1α, IL-10, AKT, and PI3K in cardiac tissue.\",\n      \"method\": \"Cardiomyocyte-specific Stat5 conditional knockout (Stat5fl/fl; Tnnt2Cre), myocardial infarct size measurement, apoptosis assays, Western blot of signaling proteins\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional tissue-specific KO with defined in vivo phenotype and mechanistic readouts, single lab\",\n      \"pmids\": [\"29365089\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TMPRSS6 expression is directly regulated by STAT5, which binds a STAT5 element in the Tmprss6 promoter; inflammation suppresses TMPRSS6 by reducing STAT5 phosphorylation through a Bmp-Smad-independent mechanism, thereby secondarily increasing hepcidin to regulate iron homeostasis.\",\n      \"method\": \"ChIP (STAT5 binding to Tmprss6 promoter), in vitro IL-6 treatment, in vivo LPS injection in mice, STAT5 phosphorylation assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct ChIP on promoter plus in vivo and in vitro functional readout, single lab\",\n      \"pmids\": [\"24376517\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"STAT5 binds directly to the Cyp19a1/aromatase promoter in macrophages to suppress its transcription; loss of STAT5 in macrophages leads to enhanced stromal aromatase expression, increased IL-6, delayed ductal elongation, and enhanced ductal branching during mammary gland development.\",\n      \"method\": \"Myeloid-specific Stat5 conditional knockout mice, ChIP (STAT5 binding to Cyp19a1 promoter), mammary gland whole-mount analysis, quantitative gene expression\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with defined phenotype plus direct ChIP validation of promoter binding, single lab\",\n      \"pmids\": [\"28606561\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"STAT5 inhibition suppresses STAT5 activation, dimerization, and nuclear translocation; the SH2 domain inhibitor AC-4-130 directly binds STAT5 and blocks its SH2-mediated dimerization, establishing the SH2 domain as essential for STAT5 activation and nuclear translocation in AML cells.\",\n      \"method\": \"Direct STAT5 binding assay, STAT5 dimerization assay, nuclear translocation assay, pharmacologic SH2 domain inhibitor, AML cell lines and patient samples in vitro and in vivo\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding plus dimerization/translocation functional assays, single lab\",\n      \"pmids\": [\"29472718\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"STAT5 tetramerization (mediated by N-domain interactions) promotes GM-CSF-induced CCL17 production by monocyte-derived cells, which in turn facilitates integrin VLA-4-dependent pathogenic Th17 cell extravasation in experimental autoimmune encephalomyelitis; STAT5 N-domain double knockin (tetramer-deficient) mice have reduced EAE pathogenesis.\",\n      \"method\": \"STAT5 tetramer-deficient knockin mice (N-domain mutations), EAE model, flow cytometry, cytokine production assays, CCL17 rescue experiments\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic model with defined domain-specific mutation plus in vivo disease model plus mechanistic rescue, single lab\",\n      \"pmids\": [\"34934004\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"STAT5A directly regulates FABP5 transcription by binding to the FABP5 promoter, thereby promoting fatty acid metabolic reprogramming and tumorigenesis in gastric cancer cells.\",\n      \"method\": \"Luciferase reporter assay, ChIP-qPCR, STAT5A knockdown, lipid content measurements, xenograft tumor models\",\n      \"journal\": \"European review for medical and pharmacological sciences\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — ChIP-qPCR plus reporter assay, single lab, limited mechanistic depth\",\n      \"pmids\": [\"31646566\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"STAT5A inhibition de-represses DLX5 expression in bone marrow stromal cells, enhancing osteogenesis; STAT5A knockout mice show increased trabecular and cortical bone mass and prevention of age-related bone loss; STAT5A deletion enhances fracture repair in a murine model.\",\n      \"method\": \"STAT5A siRNA knockdown in hBMSCs, STAT5A conditional knockout mice, micro-CT bone analysis, fracture callus histology\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO plus in vitro knockdown plus multiple skeletal phenotype readouts, single lab\",\n      \"pmids\": [\"30429452\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Phosphorylated STAT5 (pY694) downregulates NPM1 by impairing the BRCA1-BARD1 ubiquitin ligase that controls NPM1 stability; decreased NPM1 levels suppress p53 expression, enhancing cell survival; NPM1 conversely negatively regulates STAT5 phosphorylation and preserves unphosphorylated STAT5.\",\n      \"method\": \"Co-immunoprecipitation, knockdown/overexpression, ubiquitin ligase activity assays, p53 expression analysis\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — co-IP plus functional protein stability assays plus bidirectional regulatory readout, single lab\",\n      \"pmids\": [\"28005077\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"GR and STAT5 interaction requires intact DNA-binding sites for both factors; GR sites used for synergism with STAT5 at the beta-casein gene promoter are non-classical half-palindromic sites that do not function independently, establishing a novel mode of transcriptional cooperation dependent on both activated STAT5 and GR.\",\n      \"method\": \"Reporter gene assays in HC11 and COS-7 cells, promoter deletion/mutation analysis, gel shift assay\",\n      \"journal\": \"Immunobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter mutagenesis plus reporter assay in two cell systems, single lab\",\n      \"pmids\": [\"9442383\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"STAT3 restrains the JAK2-STAT5 transcriptional pathway in dendritic cells, thereby suppressing immunogenic DC function; STAT3 degradation by PROTACs reprograms the DC transcriptional network toward STAT5-driven immunogenicity, enhancing T cell priming and anti-tumor immunity.\",\n      \"method\": \"PROTAC STAT3 degraders, transcriptomic profiling of dendritic cells, T cell priming assays, in vivo tumor models\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic/pharmacologic intervention with transcriptomic and in vivo functional readout, single lab\",\n      \"pmids\": [\"40369063\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"STAT5A is a latent cytoplasmic transcription factor that is tyrosine-phosphorylated (primarily at Y694) by receptor-associated JAKs (especially JAK2) or directly by receptor tyrosine kinases (insulin receptor, Flt3-ITD) downstream of a wide range of cytokines and hormones; upon phosphorylation, STAT5A undergoes SH2-domain-mediated dimerization (and tetramerization via N-domain contacts), nuclear translocation facilitated by signaling intermediates such as PAK1, and sequence-specific DNA binding at GAS elements to activate target gene transcription; its activity is negatively regulated by multiple phosphatases (PTP1B, Shp-2, LMW-PTP); additional post-translational modifications including serine phosphorylation at S725/S779 and O-GlcNAcylation enhance its oncogenic/leukemogenic activity; unphosphorylated STAT5A has a distinct function stabilizing heterochromatin via HP1α; a mitochondrial pool of STAT5A disrupts the pyruvate dehydrogenase complex to promote the Warburg effect; and context-specific transcriptional outputs are shaped by physical interactions with co-regulators including the glucocorticoid receptor, Runx transcription factors, HMGN2/HDAC6, NMI, and STAP-2/BKS, as well as by cell-type-specific autoregulatory enhancers that amplify STAT5A expression in mammary epithelium.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"STAT5A is a latent cytoplasmic transcription factor that couples cytokine, hormone, and growth-factor receptors to sequence-specific gene activation and serves as the obligate, non-redundant mediator of prolactin-driven mammary lobuloalveolar development and lactogenesis [#0, #1]. Activation proceeds through tyrosine phosphorylation by receptor-associated JAK kinases—the JAK2 kinase domain alone is sufficient to bind and phosphorylate STAT5, and the SH2-domain residue R618 is required for this event [#10]—as well as by JAK1/JAK3 downstream of IL-2/IL-15 [#4]; STAT5 is also a direct substrate of the insulin receptor and of oncogenic Flt3-ITD independently of JAK and Src kinases [#7, #8]. Phosphorylated STAT5 dimerizes through reciprocal phosphotyrosine–SH2 contacts (the pharmacologic SH2 inhibitor AC-4-130 blocks dimerization and nuclear entry) and can further tetramerize via N-domain interactions to drive specific outputs such as GM-CSF-induced CCL17 in autoimmune inflammation [#32, #33]; nuclear translocation is promoted by a FAK–Rac1–PAK1 axis in leukemic cells [#20]. In the nucleus STAT5A binds GAS elements to control target genes including the IL-2 receptor α chain, RANKL, RAD51, and TMPRSS6, and acts through cell-type-specific and autoregulatory mammary enhancers/super-enhancers that amplify Stat5 expression and Wap induction [#3, #9, #27, #30, #23, #24]. Transcriptional output is shaped by physical partners—the glucocorticoid receptor (cooperating at non-classical half-sites), Runx1/2/3, HMGN2/HDAC6, and the negative regulator STAP-2/BKS [#2, #37, #18, #21, #13]. Signaling is terminated by the phosphatases PTP1B and Shp-2, which bind phospho-STAT5 and accelerate its dephosphorylation [#5, #6]. Beyond canonical signaling, post-translational modification by serine phosphorylation at S725/S779 and by O-GlcNAcylation is required for its leukemogenic and oncogenic activity [#15, #19], unphosphorylated STAT5A binds HP1α to stabilize heterochromatin and repress cancer-associated genes [#14], and a mitochondrial pool disrupts the pyruvate dehydrogenase complex to promote the Warburg effect [#25]. STAT5A also has tissue-specific physiological roles in erythroid and adipocyte differentiation, bone mass control, and cardioprotective ischemic preconditioning [#16, #12, #35, #29].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Established that STAT5 is not an isolated activator but physically integrates with nuclear hormone receptor signaling, forming a complex with the glucocorticoid receptor that cooperatively shapes transcriptional output.\",\n      \"evidence\": \"Co-IP, DNA-binding and reporter assays in mammalian cells, with promoter mutagenesis showing dependence on non-classical GR half-sites\",\n      \"pmids\": [\"8878484\", \"9442383\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the STAT5-GR interaction not resolved\", \"Generality of half-site cooperation beyond the beta-casein promoter not established\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Placed STAT5 downstream of IL-2-family cytokine receptors via the JAK1/JAK3 axis, linking tyrosine phosphorylation to DNA-binding complex formation.\",\n      \"evidence\": \"Phosphorylation assays, EMSA, and JAK immunoprecipitation in human T cells\",\n      \"pmids\": [\"7568001\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not distinguish STAT5A from STAT5B contributions\", \"Direct kinase-substrate relationship not reconstituted in vitro\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Genetic knockout defined STAT5A as the principal, non-redundant mediator of prolactin-induced mammary differentiation and lactation, answering whether the near-identical STAT5A/STAT5B paralogs are functionally interchangeable.\",\n      \"evidence\": \"Stat5a knockout mice, mammary histology, and lactation phenotyping; extended by individual and combined Stat5a/Stat5b knockouts\",\n      \"pmids\": [\"9009201\", \"9630227\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis for STAT5A vs STAT5B specificity at shared target genes not defined\", \"Did not identify the full mammary target gene set\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Showed STAT5 is activated by non-JAK receptor kinases, demonstrating direct phosphorylation by the insulin receptor and a requirement downstream of the erythropoietin receptor, broadening STAT5 inputs beyond cytokine JAKs.\",\n      \"evidence\": \"Yeast two-hybrid, in vitro kinase assay with purified IR domain, in vivo tissue phosphorylation; chimeric EpoR Y\\u2192F mutants and dominant-negative STAT5 in erythroleukemia cells\",\n      \"pmids\": [\"9122188\", \"9079629\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological weight of IR-direct phosphorylation versus JAK routes unresolved\", \"EpoR-STAT5 erythroid role later shown largely Stat5b/redundant in vivo\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Defined a specific STAT5A transcriptional target in immune signaling—the IL-2 receptor alpha chain—linking STAT5A loss to impaired low-affinity IL-2 proliferative responses.\",\n      \"evidence\": \"Stat5a knockout splenocytes, IL-2Ra expression analysis, and IL-2 dose-response proliferation assays\",\n      \"pmids\": [\"9390692\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct STAT5A occupancy of the IL-2Ra promoter not shown in this study\", \"Redundancy with STAT5B not addressed\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Dissected the activation mechanism, showing the JAK2 kinase domain is sufficient for STAT5 binding/phosphorylation, the SH2 residue R618 is required, and a single phosphotyrosine-SH2 contact drives dimerization but yields poorly DNA-binding dimers; also separated receptor-driven phosphorylation from nuclear translocation.\",\n      \"evidence\": \"Yeast reconstitution with integrated reporter, site-directed mutagenesis, stringent co-IP; PRLR phosphotyrosine mutant analysis with subcellular fractionation\",\n      \"pmids\": [\"9575217\", \"9516478\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural detail of high-affinity DNA-binding dimer geometry not resolved\", \"Identity of the nuclear translocation machinery downstream of PRLR Tyr382 unknown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identified the phosphatases that terminate STAT5 signaling, establishing PTP1B and Shp-2 as direct, phospho-tyrosine-dependent STAT5 inactivators with functional consequences for transcription and nuclear localization.\",\n      \"evidence\": \"In vitro phosphatase assays, substrate-trapping co-precipitation, Shp-2-null cells, reporter assays (PTP1B reported 2000)\",\n      \"pmids\": [\"10993888\", \"12615921\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative in vivo contributions of each phosphatase not ranked\", \"Spatial site of dephosphorylation (cytoplasm vs nucleus) not fully defined\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Expanded STAT5A's physiological and target-gene repertoire, defining a GAS element in the RANKL promoter, a STAT5A-sufficient adipogenic program, and a STAT5-GR association during differentiation.\",\n      \"evidence\": \"Dominant-negative JAK2/STAT5 with promoter mapping and COS7 reconstitution; ectopic STAT5A expression with adipogenesis markers and co-IP\",\n      \"pmids\": [\"12952963\", \"12540601\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"STAT5A vs STAT5B specificity in adipogenesis not mechanistically explained\", \"Endogenous-context validation of RANKL regulation limited\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Characterized regulatory and co-regulator partners that tune STAT5 activity, identifying STAP-2/BKS as a cytoplasmic negative regulator and (later) Runx1/2/3 as mutual transcriptional antagonists that retain STAT5 in the cytoplasm.\",\n      \"evidence\": \"Co-IP, domain mapping, intracellular staining, STAP-2-null thymocytes; Runx co-IP, fractionation, DNA-binding and CIS target gene readouts in Ba/F3 cells\",\n      \"pmids\": [\"15611091\", \"18296717\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Quantitative impact of these regulators on physiological STAT5 outputs unclear\", \"Single-lab co-IP evidence without reciprocal structural validation\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Connected STAT5A to G-protein-coupled receptor signaling, showing Src-dependent tyrosine phosphorylation and direct binding to the mu-opioid receptor C-terminal YXXL motif.\",\n      \"evidence\": \"Co-IP and GST pulldown from brain/COS-7 extracts, MOR motif mutagenesis, Src inhibitor PP1, STAT-responsive reporter\",\n      \"pmids\": [\"15857395\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream neuronal target genes not identified\", \"Physiological relevance in vivo not established\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Distinguished STAT5A's oncogenic from its physiological activity by showing serine phosphorylation at S725/S779 is required for leukemogenesis but dispensable for normal hematopoietic reconstitution.\",\n      \"evidence\": \"Serine-mutant complementation in Stat5-null cells and bone marrow transplantation leukemia model\",\n      \"pmids\": [\"20508164\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinase(s) responsible for S725/S779 phosphorylation not identified here\", \"Mechanism by which serine phosphorylation alters target gene selection unresolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Revealed a phosphorylation-independent function: unphosphorylated STAT5A binds HP1\\u03b1 to stabilize heterochromatin and repress cancer-associated genes, recasting the unphosphorylated pool as a tumor suppressor.\",\n      \"evidence\": \"Co-IP, transcriptome profiling, unphosphorylatable STAT5A mutant, and colon cancer xenografts; TMPRSS6 promoter ChIP also defined a direct iron-homeostasis target\",\n      \"pmids\": [\"23733954\", \"24376517\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Genome-wide map of unphosphorylated STAT5A/HP1\\u03b1 sites incomplete\", \"Switch dynamics between repressive and activating STAT5A pools not defined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defined nuclear-entry and chromatin-cooperation mechanisms in transformed cells, showing PAK1 drives STAT5 nuclear translocation downstream of FAK-Rac1, and that persistent STAT5 activation recruits p53 to shared promoters.\",\n      \"evidence\": \"FAK/PAK1 inhibitors with in vivo leukemia models and fractionation; ChIP-seq co-localization of STAT5 and p53 with inhibition experiments\",\n      \"pmids\": [\"25456130\", \"24681953\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether PAK1-driven translocation is import-receptor independent unknown\", \"Functional consequence of STAT5-p53 co-occupancy on individual genes not dissected\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Established that cell-type-specific autoregulatory and super-enhancers, decoded by in vivo CRISPR editing, amplify STAT5 levels and STAT5-dependent gene induction in mammary epithelium, explaining quantitative control of lactation genes.\",\n      \"evidence\": \"ChIP-seq, DNaseI hypersensitivity, combinatorial CRISPR/Cas9 mutagenesis in mice with transcriptome readouts; additional coactivator (HMGN2/HDAC6) and tissue-specific repressive roles (macrophage Cyp19a1, osteogenic DLX5) defined\",\n      \"pmids\": [\"26446995\", \"27376239\", \"27358110\", \"28606561\", \"30429452\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Hierarchy of trans-factors building the super-enhancer not fully resolved\", \"Mechanistic basis of repressive vs activating enhancer engagement across tissues unclear\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showed O-GlcNAcylation is a required modification for STAT5 oncogenicity, promoting tyrosine phosphorylation, oligomerization, and transformation, adding a metabolism-linked PTM layer to STAT5 activation.\",\n      \"evidence\": \"O-GlcNAc-site mutagenesis with phosphorylation, oligomerization, and transformation assays in hematopoietic cells\",\n      \"pmids\": [\"28074064\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"O-GlcNAc transferase responsible and modified residues' interplay with serine sites not defined\", \"Effect on physiological (non-oncogenic) STAT5 signaling untested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Extended STAT5 function to DNA repair, demonstrating JAK2-dependent STAT5a/b induction of RAD51 is required for homologous recombination and confers radioresistance in prostate cancer.\",\n      \"evidence\": \"Comet, clonogenic, HR/NHEJ reporter assays, siRNA, xenografts, and patient-derived 3D explants; cardiomyocyte-specific Stat5 KO also defined an ischemic-preconditioning cardioprotective role\",\n      \"pmids\": [\"29483142\", \"29365089\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct STAT5 occupancy of the RAD51 promoter not detailed here\", \"Mechanism linking STAT5 to the apoptotic/HIF-1\\u03b1 program in cardiomyocytes incompletely mapped\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined oligomerization-state and non-nuclear functions, showing N-domain tetramerization drives a specific cytokine output (CCL17) in autoimmunity and that a mitochondrial STAT5A pool disrupts the pyruvate dehydrogenase complex to enforce the Warburg effect.\",\n      \"evidence\": \"Tetramer-deficient N-domain knockin mice in EAE with rescue; STAT5A-PDC co-IP, PDC activity and metabolic profiling, hypoxia, and xenografts\",\n      \"pmids\": [\"34934004\", \"34148062\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Import mechanism for mitochondrial STAT5A unknown\", \"Structural basis distinguishing dimer vs tetramer target selection unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Revealed post-transcriptional and feedback control of STAT5A itself, with YTHDF2-mediated m6A decay of STAT5A mRNA relieving STAT5A-dependent repression of the MAP2K2/ERK pathway, and pY694-STAT5 modulating NPM1/p53 stability.\",\n      \"evidence\": \"m6A-RIP-seq, RIP-PCR, ChIP-seq/qPCR and functional assays in myeloma; co-IP and ubiquitin-ligase/protein-stability assays for the NPM1-p53 axis\",\n      \"pmids\": [\"35075244\", \"28005077\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Generality of STAT5A as an ERK-pathway repressor beyond myeloma unknown\", \"Bidirectional STAT5-NPM1 regulation not validated in primary cells\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Positioned the JAK2-STAT5 axis as a determinant of dendritic-cell immunogenicity restrained by STAT3, showing STAT3 degradation reprograms DCs toward STAT5-driven anti-tumor T cell priming.\",\n      \"evidence\": \"STAT3 PROTAC degraders, DC transcriptomics, T cell priming assays, in vivo tumor models\",\n      \"pmids\": [\"40369063\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct STAT5 target genes mediating DC immunogenicity not enumerated\", \"Mechanism of STAT3 restraint over JAK2-STAT5 not biochemically defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the same protein is partitioned among activating dimers/tetramers, repressive unphosphorylated heterochromatin complexes, and a metabolic mitochondrial pool—and what governs the switch between these states in a given cell—remains unresolved.\",\n      \"evidence\": \"No single study in the corpus integrates the competing STAT5A states or provides structural/quantitative models of their interconversion\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No unified structural model of dimer/tetramer/monomer interconversion\", \"Signals controlling mitochondrial import are unknown\", \"Quantitative balance of nuclear-activating vs repressive pools per cell type undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 3, 9, 24, 27, 30, 31, 28]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [9, 23, 24, 30, 31, 28]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [25]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [13, 18, 32]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [5, 11, 20, 32]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [14]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [25]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4, 7, 8, 10]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [3, 9, 24, 30, 31]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [0, 1, 12, 16, 23, 24, 35]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [3, 4, 33, 38]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [8, 15, 19, 27]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [27]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [25, 34]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [14]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"GR\", \"JAK2\", \"PTP1B\", \"SHP2\", \"RUNX1\", \"STAP2\", \"HP1A\", \"NPM1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}